ifosfamide has been researched along with Bone Marrow Diseases in 23 studies
Bone Marrow Diseases: Diseases involving the BONE MARROW.
| Excerpt | Relevance | Reference |
|---|---|---|
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 9.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin." | 9.07 | Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. ( Blum, RH; Brooks, JS; Edmonson, JH; Frytak, S; Parkinson, DR; Ryan, LM; Shiraki, M, 1993) |
| "The Southwest Oncology Group (SWOG) performed a phase II trial of a combination of ifosfamide/mesna/cisplatin in patients with metastatic soft-tissue sarcoma who had previously received one chemotherapeutic regimen." | 9.07 | Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. ( Balcerzak, SP; Budd, GT; Fabian, C; Metch, B; Stephens, RL; Weick, JK; Weiss, SA, 1993) |
| "Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide." | 9.06 | Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group. ( de Kraker, J; Hartmann, O; Ninane, J; Pritchard, J, 1987) |
| "Ten children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor of the posterior fossa were treated with total surgical resection, radiation therapy, and ICE chemotherapy regimen with ifosfamide (900 mg/m2, days 1-5), cisplatin (20 mg/m2, days 1-5), and etoposide (60 mg/m2, days 1-5) every 4 weeks for eight cycles." | 7.69 | Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study. ( Abe, H; Ikeda, J; Ishii, N; Kato, T; Sawamura, Y; Shirato, H; Tada, M, 1996) |
| "A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)." | 7.68 | Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993) |
| "One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial." | 7.67 | Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 6.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 5.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin." | 5.07 | Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. ( Blum, RH; Brooks, JS; Edmonson, JH; Frytak, S; Parkinson, DR; Ryan, LM; Shiraki, M, 1993) |
| "The Southwest Oncology Group (SWOG) performed a phase II trial of a combination of ifosfamide/mesna/cisplatin in patients with metastatic soft-tissue sarcoma who had previously received one chemotherapeutic regimen." | 5.07 | Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. ( Balcerzak, SP; Budd, GT; Fabian, C; Metch, B; Stephens, RL; Weick, JK; Weiss, SA, 1993) |
| "Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide." | 5.06 | Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group. ( de Kraker, J; Hartmann, O; Ninane, J; Pritchard, J, 1987) |
| "Ten children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor of the posterior fossa were treated with total surgical resection, radiation therapy, and ICE chemotherapy regimen with ifosfamide (900 mg/m2, days 1-5), cisplatin (20 mg/m2, days 1-5), and etoposide (60 mg/m2, days 1-5) every 4 weeks for eight cycles." | 3.69 | Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study. ( Abe, H; Ikeda, J; Ishii, N; Kato, T; Sawamura, Y; Shirato, H; Tada, M, 1996) |
| "This study was designed to test the feasibility of administering doxorubicin at an optimal dose-intensity (> 70 mg/m2 per 21 days) in combination with ifosfamide under recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) cover in patients with metastatic soft tissue sarcomas." | 3.68 | Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Grou ( Clavel, M; Crowther, D; Kerbrat, P; Rouesse, J; Somers, R; Spooner, D; Steward, WP; Tueni, E; Tursz, T; Verweij, J, 1993) |
| "A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)." | 3.68 | Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993) |
| "We gave the "optimal" dose of doxorubicin (75 mg/m2) with ifosfamide (5 g/m2), the two most active agents against metastatic soft-tissue sarcomas, in an attempt to determine the feasibility of administration of these doses in combination." | 3.68 | The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Clavel, M; Crowther, D; Kerbrat, P; Rouesse, J; Somers, R; Spooner, D; Steward, WP; Tueni, E; Tursz, T; Verweij, J, 1993) |
| "One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial." | 3.67 | Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 2.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| " Peak concentration of 47 micrograms/ml was observed after 1 h." | 2.70 | Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients. ( Gasiorek, M; Kobylińska, K; Kobylińska, M; Koralewski, P; Sobik, B, 2001) |
| "Patients with metastatic cancers were treated with GM-CSF at 5 micrograms/kg sc, days 1 to 7; leukaphereses were performed on days 6 and 7." | 2.68 | Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor. ( Balcerzak, SP; Benzies, T; Triozzi, PL; Tucker, F, 1996) |
| "The tolerance for and activity of escalating targeted doses of carboplatin combined with ifosfamide and etoposide (ICE) were assessed in children with advanced germ cell tumors or other rare solid tumors for which no standard therapy exists." | 2.67 | Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. ( Bowman, LC; Furman, W; Jones, DP; Marina, NM; Meyer, WH; Murry, DJ; Pratt, CB; Rodman, JH; Shema, SJ, 1994) |
| " However on multivariate analysis only the presence of bulky disease and of B symptoms were independent adverse factors for response and for survival." | 2.67 | EPIC: an effective low toxicity regimen for relapsing lymphoma. ( Ashley, S; Catovsky, D; Cunningham, D; Gore, ME; Hickish, T; Mansi, J; Nicolson, V; Roldan, A; Smith, IE, 1993) |
| " With future identification of effective chemotherapy, new studies may be focused upon patients with localized disease to reduce radiation dosage or the need for immediate surgical resection of all involved eyes." | 1.27 | The use of chemotherapy for extraocular retinoblastoma. ( Crom, DB; Howarth, C; Pratt, CB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 16 (69.57) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schütt, P | 1 |
| Passon, J | 1 |
| Ebeling, P | 1 |
| Welt, A | 1 |
| Müller, S | 1 |
| Metz, K | 1 |
| Moritz, T | 1 |
| Seeber, S | 1 |
| Nowrousian, MR | 1 |
| Marina, NM | 1 |
| Rodman, JH | 1 |
| Murry, DJ | 1 |
| Shema, SJ | 1 |
| Bowman, LC | 1 |
| Jones, DP | 1 |
| Furman, W | 1 |
| Meyer, WH | 2 |
| Pratt, CB | 3 |
| Edmonson, JH | 1 |
| Ryan, LM | 1 |
| Blum, RH | 1 |
| Brooks, JS | 1 |
| Shiraki, M | 1 |
| Frytak, S | 1 |
| Parkinson, DR | 1 |
| Hickish, T | 1 |
| Roldan, A | 1 |
| Cunningham, D | 1 |
| Mansi, J | 1 |
| Ashley, S | 1 |
| Nicolson, V | 1 |
| Gore, ME | 1 |
| Catovsky, D | 1 |
| Smith, IE | 1 |
| Steward, WP | 2 |
| Verweij, J | 2 |
| Somers, R | 2 |
| Spooner, D | 2 |
| Kerbrat, P | 2 |
| Clavel, M | 2 |
| Crowther, D | 2 |
| Rouesse, J | 2 |
| Tursz, T | 2 |
| Tueni, E | 2 |
| Budd, GT | 1 |
| Metch, B | 1 |
| Weiss, SA | 1 |
| Weick, JK | 1 |
| Fabian, C | 1 |
| Stephens, RL | 1 |
| Balcerzak, SP | 2 |
| Toma, S | 1 |
| Palumbo, R | 1 |
| Canavese, G | 1 |
| Albanese, E | 1 |
| Cantoni, E | 1 |
| Barisone, A | 1 |
| Reggiardo, G | 1 |
| Rosso, R | 1 |
| Santi, L | 1 |
| Hoelzer, D | 1 |
| Ludwig, WD | 1 |
| Thiel, E | 1 |
| Gassmann, W | 1 |
| Löffler, H | 1 |
| Fonatsch, C | 1 |
| Rieder, H | 1 |
| Heil, G | 1 |
| Heinze, B | 1 |
| Arnold, R | 1 |
| Hossfeld, D | 1 |
| Büchner, T | 1 |
| Koch, P | 1 |
| Freund, M | 1 |
| Hiddemann, W | 1 |
| Maschmeyer, G | 1 |
| Heyll, A | 1 |
| Aul, C | 1 |
| Faak, T | 1 |
| Kuse, R | 1 |
| Ittel, TH | 1 |
| Gramatzki, M | 1 |
| Diedrich, H | 1 |
| Kolbe, K | 1 |
| Fuhr, HG | 1 |
| Fischer, K | 1 |
| Schadeck-Gressel, C | 1 |
| Weiss, A | 1 |
| Strohscheer, I | 1 |
| Metzner, B | 1 |
| Fabry, U | 1 |
| Gökbuget, N | 1 |
| Völkers, B | 1 |
| Messerer, D | 1 |
| Uberla, K | 1 |
| Ciaudo, M | 1 |
| Chauvenet, L | 1 |
| Audouin, J | 1 |
| Rossert, J | 1 |
| Favier, R | 1 |
| Horellou, MH | 1 |
| Bernadou, A | 1 |
| Samama, M | 1 |
| Triozzi, PL | 1 |
| Tucker, F | 1 |
| Benzies, T | 1 |
| Sawamura, Y | 1 |
| Ikeda, J | 1 |
| Ishii, N | 1 |
| Kato, T | 1 |
| Tada, M | 1 |
| Abe, H | 1 |
| Shirato, H | 1 |
| Fetscher, S | 2 |
| Brugger, W | 2 |
| Engelhardt, R | 2 |
| Kanz, L | 2 |
| Hasse, J | 2 |
| Frommhold, H | 2 |
| Wenger, M | 2 |
| Lange, W | 2 |
| Mertelsmann, R | 2 |
| Furman, WL | 1 |
| Luo, X | 1 |
| Fairclough, D | 1 |
| Garrison, L | 1 |
| Marina, N | 1 |
| Bleyer, A | 1 |
| Hempling, RE | 1 |
| Eltabbakh, GH | 1 |
| Piver, MS | 1 |
| Recio, FO | 1 |
| O'Neill, CP | 1 |
| Beyer, J | 1 |
| Rick, O | 1 |
| Weinknecht, S | 1 |
| Kingreen, D | 1 |
| Lenz, K | 1 |
| Siegert, W | 1 |
| Fulda, S | 1 |
| Fichtner, I | 1 |
| Hero, B | 1 |
| Berthold, F | 1 |
| Kobylińska, K | 1 |
| Koralewski, P | 1 |
| Sobik, B | 1 |
| Gasiorek, M | 1 |
| Kobylińska, M | 1 |
| Breitfeld, PP | 1 |
| Lyden, E | 1 |
| Raney, RB | 1 |
| Teot, LA | 1 |
| Wharam, M | 1 |
| Lobe, T | 1 |
| Crist, WM | 1 |
| Maurer, HM | 1 |
| Donaldson, SS | 1 |
| Ruymann, FB | 1 |
| Miser, JS | 1 |
| Kinsella, TJ | 1 |
| Triche, TJ | 1 |
| Tsokos, M | 1 |
| Jarosinski, P | 1 |
| Forquer, R | 1 |
| Wesley, R | 1 |
| Magrath, I | 1 |
| de Kraker, J | 1 |
| Pritchard, J | 1 |
| Hartmann, O | 1 |
| Ninane, J | 1 |
| Crom, DB | 1 |
| Howarth, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153] | Phase 2 | 41 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma[NCT01755195] | Phase 2 | 55 participants (Actual) | Interventional | 2013-01-15 | Active, not recruiting | ||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007] | Phase 2/Phase 3 | 37 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Late Effects of Treatment in Survivors of Pediatric Sarcomas[NCT00006515] | 39 participants (Actual) | Observational | 2000-11-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cabozantinib | 53 |
Objective response was assessed by the Response Evaluation Criteria in Solid Tumors RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.
| Intervention | percentage of particpants (Number) |
|---|---|
| Cabozantinib | 11.1 |
Progression in participants with soft tissue sarcomas treated with cabozantinib was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. (NCT01755195)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Cabozantinib | 49.3 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of HGF. HGF protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
| Cabozantinib | -51.3 | 344.8 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble MET (sMET). sMET protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day1 | |
| Cabozantinib | -6.1 | 16.4 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble VEGFR2 (sVEGFR-2). sVEGFR-2 protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
| Cabozantinib | -1.0 | -10.9 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of VEGF-A. VEGF-A protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
| Cabozantinib | 5.6 | 32.5 |
15 trials available for ifosfamide and Bone Marrow Diseases
| Article | Year |
|---|---|
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Thera | 2007 |
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Child; Child, Pre | 1994 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
EPIC: an effective low toxicity regimen for relapsing lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Drug A | 1993 |
Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cispl | 1993 |
Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
Topics: Adult; Aged; Antigen-Presenting Cells; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; | 1996 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carc | 1997 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Neoplasms; C | 1997 |
Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow; Bon | 1997 |
The addition of bleomycin and dose-escalated ifosfamide to the combination of cisplatin plus ifosfamide does not improve survival in advanced or recurrent cervical carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1997 |
Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bo | 1997 |
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Divi | 2001 |
Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Blood Cell Count; B | 2001 |
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bronchiolit | 2001 |
Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group.
Topics: Bone Marrow Diseases; Child; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Male; Neuroblas | 1987 |
8 other studies available for ifosfamide and Bone Marrow Diseases
| Article | Year |
|---|---|
Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Grou
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Disea | 1993 |
Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1993 |
The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Doxorubicin; Fema | 1993 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Peripheral-T-cell lymphoma with hemophagocytic histiocytosis localised to the bone marrow associated with inappropriate secretion of antidiuretic hormone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Cy | 1995 |
Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Cerebellar Neopla | 1996 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
The use of chemotherapy for extraocular retinoblastoma.
Topics: Bone Marrow Diseases; Brain Neoplasms; Child; Cyclophosphamide; Doxorubicin; Drug Evaluation; Eye Ne | 1985 |